Cargando…
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England
BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935297/ https://www.ncbi.nlm.nih.gov/pubmed/36933983 http://dx.doi.org/10.1016/j.vaccine.2023.02.047 |
_version_ | 1784890015109611520 |
---|---|
author | Meyer, Carly Goffe, Louis Antonopoulou, Vivi Graham, Fiona Tang, Mei Yee Lecouturier, Jan Grimani, Aikaterini Chadwick, Paul Sniehotta, Falko F. |
author_facet | Meyer, Carly Goffe, Louis Antonopoulou, Vivi Graham, Fiona Tang, Mei Yee Lecouturier, Jan Grimani, Aikaterini Chadwick, Paul Sniehotta, Falko F. |
author_sort | Meyer, Carly |
collection | PubMed |
description | BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To use the Precaution Adoption Process Model (PAPM) to understand decision-making about the COVID-19 booster vaccine (CBV) in England. METHODS: An online, cross-sectional survey informed by the PAPM, the extended Theory of Planned Behaviour and Health Belief Model administered to people over the age of 50 residing in England, UK in October 2021. A multivariate, multinomial logistic regression model was used to examine associations with the different stages of CBV decision-making. RESULTS: Of the total 2,004 participants: 135 (6.7%) were unengaged with the CBV programme; 262 (13.1%) were undecided as to whether to have a CBV; 31 (1.5%) had decided not to have a CBV; 1,415 (70.6%) had decided to have a CBV; and 161 (8.0%) had already had their CBV. Being unengaged was positively associated with beliefs in their immune system to protect against COVID-19, being employed, and low household income; and negatively associated with CBV knowledge, a positive COVID-19 vaccine experience, subjective norms, anticipated regret of not having a CBV, and higher academic qualifications. Being undecided was positively associated with beliefs in their immune system and having previously received the Oxford/AstraZeneca (as opposed to Pfizer/BioNTech) vaccine; and negatively associated with CBV knowledge, positive attitudes regarding CBV, a positive COVID-19 vaccine experience, anticipated regret of not having a CBV, white British ethnicity, and living in East Midlands (vs London). CONCLUSIONS: Public health interventions promoting CBV may improve uptake through tailored messaging directed towards the specific decision stage relating to having a COVID-19 booster. |
format | Online Article Text |
id | pubmed-9935297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | The Authors. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-99352972023-02-17 Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England Meyer, Carly Goffe, Louis Antonopoulou, Vivi Graham, Fiona Tang, Mei Yee Lecouturier, Jan Grimani, Aikaterini Chadwick, Paul Sniehotta, Falko F. Vaccine Article BACKGROUND: COVID-19 continues to pose a threat to public health. Booster vaccine programmes are critical to maintain population-level immunity. Stage theory models of health behaviour can help our understanding of vaccine decision-making in the context of perceived threats of COVID-19. PURPOSE: To use the Precaution Adoption Process Model (PAPM) to understand decision-making about the COVID-19 booster vaccine (CBV) in England. METHODS: An online, cross-sectional survey informed by the PAPM, the extended Theory of Planned Behaviour and Health Belief Model administered to people over the age of 50 residing in England, UK in October 2021. A multivariate, multinomial logistic regression model was used to examine associations with the different stages of CBV decision-making. RESULTS: Of the total 2,004 participants: 135 (6.7%) were unengaged with the CBV programme; 262 (13.1%) were undecided as to whether to have a CBV; 31 (1.5%) had decided not to have a CBV; 1,415 (70.6%) had decided to have a CBV; and 161 (8.0%) had already had their CBV. Being unengaged was positively associated with beliefs in their immune system to protect against COVID-19, being employed, and low household income; and negatively associated with CBV knowledge, a positive COVID-19 vaccine experience, subjective norms, anticipated regret of not having a CBV, and higher academic qualifications. Being undecided was positively associated with beliefs in their immune system and having previously received the Oxford/AstraZeneca (as opposed to Pfizer/BioNTech) vaccine; and negatively associated with CBV knowledge, positive attitudes regarding CBV, a positive COVID-19 vaccine experience, anticipated regret of not having a CBV, white British ethnicity, and living in East Midlands (vs London). CONCLUSIONS: Public health interventions promoting CBV may improve uptake through tailored messaging directed towards the specific decision stage relating to having a COVID-19 booster. The Authors. Published by Elsevier Ltd. 2023-04-06 2023-02-17 /pmc/articles/PMC9935297/ /pubmed/36933983 http://dx.doi.org/10.1016/j.vaccine.2023.02.047 Text en © 2023 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Meyer, Carly Goffe, Louis Antonopoulou, Vivi Graham, Fiona Tang, Mei Yee Lecouturier, Jan Grimani, Aikaterini Chadwick, Paul Sniehotta, Falko F. Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title | Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title_full | Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title_fullStr | Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title_full_unstemmed | Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title_short | Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England |
title_sort | using the precaution adoption process model to understand decision-making about the covid-19 booster vaccine in england |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9935297/ https://www.ncbi.nlm.nih.gov/pubmed/36933983 http://dx.doi.org/10.1016/j.vaccine.2023.02.047 |
work_keys_str_mv | AT meyercarly usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT goffelouis usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT antonopoulouvivi usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT grahamfiona usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT tangmeiyee usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT lecouturierjan usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT grimaniaikaterini usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT chadwickpaul usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland AT sniehottafalkof usingtheprecautionadoptionprocessmodeltounderstanddecisionmakingaboutthecovid19boostervaccineinengland |